The paradigm of personalized therapy in oncology

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Gasparini, Giampietro ^a   Longo, Raffaele ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Predictive biomarkers; Study design; Targeted anticancer agents

Indexed keywords

AFATINIB; CABOZANTINIB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CRIZOTINIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; LETROZOLE; MAYTANSINE; MK 2206; NERATINIB; NILOTINIB; PACLITAXEL; PELITINIB; PEMETREXED; PERTUZUMAB; PLATINUM; PROTEIN KINASE B INHIBITOR; RILOTUMUMAB; SELUMETINIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CELL HETEROGENEITY; COLORECTAL CANCER; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; ONCOGENE C KIT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MELANOMA; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84857597802     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.637921     Document Type: Review

References (66)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;44:646-74
2. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2000;1:267-73
3. Ashman LK. The biology of stem cell factor and its receptor c-kit. Int J Biochem Cell Biol 1999;31:1037-51 (Pubitemid 29454545)
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6 (Pubitemid 32267975)
5. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80 (Pubitemid 34879334)
6. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8 (Pubitemid 35155011)
7. Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010;15:300-7
8. Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2010;21:208-15
9. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7
10. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66
11. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011;37:291-9
12. Sarcoma Alliance for Research through Collaboration. Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients. ClinicalTrials. gov NCT01031628. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01031628?term=NCT01031628&rank=1
13. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38 (Pubitemid 44528723)
14. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80
15. Mok TS, Wu YL, Thogprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
16. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase III trial. Lancet Oncol 2010;11:121-8
17. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for Non-Small-Cell Lung Cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
18. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study. Lancet Oncol 2011;12:735-42
19. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-AKT fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6 (Pubitemid 47206930)
20. Horn L, Pao W. EML4-AKT:honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009;27:4247-53
21. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-6
22. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;119:1642-6 (Pubitemid 40478587)
23. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-71 (Pubitemid 47353042)
24. Testa JR, Bellacosa A. AKT plays a centralrole in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-5
25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54 (Pubitemid 34716871)
26. Reichardt P, Montemurro M. Clinical experience to date with nilotinib in gastrointestinal stromal tumors. Semin Oncol 2011;38(Suppl 1):S20-7
27. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signalling pathway genes in lung adenocarcinoma. Cancer Res 2008;68:5524-8
28. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43 (Pubitemid 46799492)
29. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82 (Pubitemid 17231334)
30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72 (Pubitemid 41464705)
32. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84 (Pubitemid 41464706)
33. Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 2010;10(Suppl 3):S72-8
34. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32
35. Vogel CL, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2, in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. In: 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl 15):abstract 1017
36. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43 (Pubitemid 46021510)
37. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9 (Pubitemid 43259947)
38. Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006;13(Suppl 1):S45-51 (Pubitemid 46219248)
39. Johnston S, Pippen JE, Pivot X Jr, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
40. Frassoldati A, Guarneri V, Piacentini F, et al. Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, Phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin Breast Cancer 2008;8:97-100 (Pubitemid 351346237)
41. Guarneri V, Frassoldati A, Piacentini F, et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 2008;8:192-4 (Pubitemid 351655936)
42. Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. In: 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl 15):abstract 1004
43. Nemunaitis J, Eiseman I, Cunningham C, et al. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846-53 (Pubitemid 40685605)
44. Erlichman C, Hidalgo M, Boni JP, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006;24:2252-60 (Pubitemid 46630654)
45. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbBsignaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28 (Pubitemid 38482068)
46. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6 (Pubitemid 38523885)
47. Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008;17:1553-8
48. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
49. Rizzo S, Bronte G, Fanale D, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010;36(Suppl 3):S56-61
50. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
51. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase III MRC COIN trial. Lancet 2011;377:2103-14
52. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009
53. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
54. Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res 2011;17:4922-8
55. Chapman PB, Hauschild A, Robert C, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
56. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011;19:11-15
57. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 2011;145:19-24
58. Smith AD, Shah SN, Rini BI, et al. Morphology, Attenuation, Size, and Structure (MASS) Criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am J Radiol 2010;194:1470-8
59. Apostolopoulos DJ, Dimitrakopoulou-Strauss A, Hohenberger P, et al. Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2011;38:1212-23
60. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507
61. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Med 2011;17:320-9
62. Rossetto D, Truman AW, Kron SJ, Cote J. Epigenetic modifications in double-strand break DNA damage signalling and repair. Clin Cancer Res 2010;16:4543-52
63. Solmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell 2011;146:353-8
64. Lang J-Yu, Hsu JL, Meric-Bernstam F, et al. BiKDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56
65. Mendelsohn J. A national cancer clinical trials system for targeted therapies. Sci Transl Med 2011;3:72-6
66. Majewski IJ, Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011;17:304-12